短期大剂量爱普列特联合坦洛新治疗前列腺增生症并尿潴留54例临床观察

Clinical Observation on Short-Term High-Dose Epristeride Combined with Tamsulosin for Treating Prostatic Hyperplasia and Urinary Retention in 54 Cases

目的观察短期大剂量爱普列特联合坦洛新治疗前列腺增生症并尿潴留的疗效及安全性。方法选择医院2014年12月至2015年12月诊治的前列腺增生症并尿潴留患者108例,采用随机数字表法分为对照组和观察组,各54例。对照组患者口服爱普列特片(每次5 mg,每日2次)联合盐酸坦洛新缓释胶囊(每次0.2 mg,每日1次)治疗,观察组患者口服爱普列特片(每次10 mg,每日2次)联合盐酸坦洛新缓释胶囊(每次0.4 mg,每日1次)治疗。两组疗程均为4周。结果治疗后,两组患者前列腺体积均缩小、残余尿量均减少、国际前列腺症状(IPSS)评分均降低,最大尿流速均增加(P<0.05),其中观察组患者前列腺体积为(88.2±4.3)cm3,IPSS评分为(11.4±1.5)分,残余尿量为(31.0±3.8)m L,明显低于对照组患者的(98.3±5.1)cm3,(14.6±1.7)分,(37.5±4.3)m L(P<0.01);观察组患者最大尿流速为(22.4±2.9)m L/s,总有效率为98.15%,明显高于对照组患者的(19.1±3.4)m L/s和87.04%(P<0.05);两组患者不良反应(头晕头痛、低血压、鼻塞)发生率相当(P>0.05)。结论短期大剂量爱普列特联合坦洛新治疗前列腺增生症并尿潴留安全有效,值得推广。

Objective To investigate clinical effect and safety of short- term high- dose epristeride combined with tamsulosin in the treatment of prostatic hyperplasia and urinary retention. Methods Totally 108 patients with prostatic hyperplasia and urinary retention admitted to our hospital from December 2014 to December 2015 were selected and divided into the control group and the observation group according to the random number table method,54 cases in each group. The control group was treated with epristeride（5 rag/time, 2 times/d） combined with Tamsulosin Hydrochloride Sustained-Release Capsules（0.2 rag/time,1 time/d）,while the observation group was treated with epristeride（10 rag/time,2 times/d） combined with Tamsulosin Hydrochloride Sustained-Release Capsules（0. 4 rag/time, 1 time/d）. The two groups were treated for 4 weeks. Results After treatment,the prostate volume, residual urine volume（RUV）,IPSS score in two groups were decreased,but the maximum urinary flow rates in two groups were increased（P 〈 0.05）. In the observation group, the prostate volume was （88.2 ± 4. 3） cm3, IPSS score was （11.4 ± 1.5） points, residual urine volume was （31.0 ± 3.8） mL, which were significantly lower than （98.3 ±5. 1） cm3, （14. 6 ± 1.7） points, （37.5 ±4.3） mL in the control group（P 〈 0.01）. The maximum urinary flow rate and the total effective rate in obsmvation group were （22.4 ±2. 9） mL/s and 98. 15% ,respectively,whichwere significantly higher than （19. 1±3.4） mL/s and 87.04% in the control group（P 〈 0. 05）. There was no significant difference in the incidence rate of adverse reactions（dizziness,headache,hypotension and nasal obstruction） between the two groups（P 〉 0.05）. Conclusion Short- term high- dose combined with tamsulosin is safe and effective in the treatment of prostatic hyperplasia and urinary retention,which is worthy of promotion.